Supernus Pharmaceuticals PE Ratio 2011-2024 | SUPN
Current and historical p/e ratio for Supernus Pharmaceuticals (SUPN) from 2011 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Supernus Pharmaceuticals PE ratio as of December 20, 2024 is 26.90.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Supernus Pharmaceuticals PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2024-12-20 |
35.43 |
|
33.11 |
| 2024-09-30 |
31.18 |
$1.07 |
29.14 |
| 2024-06-30 |
26.75 |
$0.09 |
297.22 |
| 2024-03-31 |
34.11 |
$-0.29 |
0.00 |
| 2023-12-31 |
28.94 |
$-0.00 |
0.00 |
| 2023-09-30 |
27.57 |
$0.41 |
67.24 |
| 2023-06-30 |
30.06 |
$0.73 |
41.18 |
| 2023-03-31 |
36.23 |
$0.89 |
40.71 |
| 2022-12-31 |
35.67 |
$1.03 |
34.63 |
| 2022-09-30 |
33.85 |
$0.64 |
52.89 |
| 2022-06-30 |
28.92 |
$1.01 |
28.63 |
| 2022-03-31 |
32.32 |
$1.30 |
24.86 |
| 2021-12-31 |
29.16 |
$0.98 |
29.76 |
| 2021-09-30 |
26.67 |
$1.51 |
17.66 |
| 2021-06-30 |
30.79 |
$1.85 |
16.64 |
| 2021-03-31 |
26.18 |
$2.07 |
12.65 |
| 2020-12-31 |
25.16 |
$2.36 |
10.66 |
| 2020-09-30 |
20.84 |
$2.41 |
8.65 |
| 2020-06-30 |
23.75 |
$2.21 |
10.75 |
| 2020-03-31 |
17.99 |
$2.17 |
8.29 |
| 2019-12-31 |
23.72 |
$2.11 |
11.24 |
| 2019-09-30 |
27.48 |
$1.97 |
13.95 |
| 2019-06-30 |
33.09 |
$1.95 |
16.97 |
| 2019-03-31 |
35.04 |
$1.91 |
18.35 |
| 2018-12-31 |
33.22 |
$2.06 |
16.13 |
| 2018-09-30 |
50.35 |
$1.84 |
27.36 |
| 2018-06-30 |
59.85 |
$1.61 |
37.17 |
| 2018-03-31 |
45.80 |
$1.36 |
33.68 |
| 2017-12-31 |
39.85 |
$1.06 |
37.59 |
| 2017-09-30 |
40.00 |
$1.06 |
37.74 |
| 2017-06-30 |
43.10 |
$1.95 |
22.10 |
| 2017-03-31 |
31.30 |
$1.81 |
17.29 |
| 2016-12-31 |
25.25 |
$1.70 |
14.85 |
| 2016-09-30 |
24.73 |
$1.58 |
15.65 |
| 2016-06-30 |
20.37 |
$0.48 |
42.44 |
| 2016-03-31 |
15.25 |
$0.33 |
46.21 |
| 2015-12-31 |
13.44 |
$0.27 |
49.78 |
| 2015-09-30 |
14.03 |
$0.23 |
61.00 |
| 2015-06-30 |
16.98 |
$0.54 |
31.44 |
| 2015-03-31 |
12.09 |
$0.59 |
20.49 |
| 2014-12-31 |
8.30 |
$0.19 |
43.68 |
| 2014-09-30 |
8.69 |
$-0.56 |
0.00 |
| 2014-06-30 |
10.95 |
$-1.73 |
0.00 |
| 2014-03-31 |
8.94 |
$-2.70 |
0.00 |
| 2013-12-31 |
7.54 |
$-2.92 |
0.00 |
| 2013-09-30 |
7.33 |
$-2.78 |
0.00 |
| 2013-06-30 |
6.43 |
$-2.55 |
0.00 |
| 2013-03-31 |
5.62 |
$-2.27 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.975B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
